Association between inflammation, angiopoietins, and disease severity in critically ill COVID-19 patients: a prospective study.
作者信息
Abou-Arab Osama, Bennis Youssef, Gauthier Pierre, Boudot Cedric, Bourdenet Gwladys, Gubler Brigitte, Beyls Christophe, Dupont Hervé, Kamel Said, Mahjoub Yazine
机构信息
Department of Anesthesia and Critical Care Medicine, Amiens University Medical Centre, Amiens, France; EA 7517, Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires, Centre Universitaire de Recherche en Santé, Amiens, France.
EA 7517, Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires, Centre Universitaire de Recherche en Santé, Amiens, France.
出版信息
Br J Anaesth. 2021 Mar;126(3):e127-e130. doi: 10.1016/j.bja.2020.12.017. Epub 2020 Dec 23.
Abstract
摘要
相似文献
1
Association between inflammation, angiopoietins, and disease severity in critically ill COVID-19 patients: a prospective study.危重症COVID-19患者炎症、血管生成素与疾病严重程度之间的关联：一项前瞻性研究。
Br J Anaesth. 2021 Mar;126(3):e127-e130. doi: 10.1016/j.bja.2020.12.017. Epub 2020 Dec 23.
2
3
Thromboinflammatory state and venous thromboembolic events in patients with coronavirus disease 2019 admitted to a nonintensive care unit: a prospective study.2019冠状病毒病非重症监护病房患者的血栓炎症状态与静脉血栓栓塞事件：一项前瞻性研究
Pol Arch Intern Med. 2021 Jan 29;131(1):86-89. doi: 10.20452/pamw.15625. Epub 2020 Sep 25.
4
Lactate dehydrogenase, COVID-19 and mortality.乳酸脱氢酶、新型冠状病毒肺炎与死亡率
Med Clin (Barc). 2021 Jan 8;156(1):37. doi: 10.1016/j.medcli.2020.07.043. Epub 2020 Sep 25.
5
Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19.C反应蛋白水平升高可能是预测新冠病毒疾病严重程度风险的早期标志物。
J Med Virol. 2020 Nov;92(11):2409-2411. doi: 10.1002/jmv.26097. Epub 2020 Jun 9.
6
A Two-Biomarker Model Predicts Mortality in the Critically Ill with Sepsis.一种双生物标志物模型可预测重症脓毒症患者的死亡率。
Am J Respir Crit Care Med. 2017 Oct 15;196(8):1004-1011. doi: 10.1164/rccm.201611-2307OC.
7
Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.在住院的 COVID-19 患者中，心脏损伤、炎症和凝血生物标志物与结局的纵向相关性。
J Mol Cell Cardiol. 2020 Oct;147:74-87. doi: 10.1016/j.yjmcc.2020.08.008. Epub 2020 Aug 20.
8
Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers.预测 COVID-19 患者的疾病严重程度和结局：多种生物标志物的综述。
Arch Pathol Lab Med. 2020 Dec 1;144(12):1465-1474. doi: 10.5858/arpa.2020-0471-SA.
9
Endothelial function in patients with metabolic syndrome and erectile dysfunction: a question of angiopoietin imbalance?代谢综合征和勃起功能障碍患者的血管内皮功能：血管生成素失衡的问题？
Andrology. 2013 Jul;1(4):541-8. doi: 10.1111/j.2047-2927.2013.00102.x.
10
Serial inflammatory biomarkers of the severity, course and outcome of late onset acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new-onset fever.新发发热后患有或有患迟发性急性呼吸窘迫综合征风险的危重症患者中，该综合征严重程度、病程及预后的系列炎症生物标志物
Biomark Med. 2015;9(6):605-16. doi: 10.2217/bmm.15.15.
引用本文的文献
1
Angiopoietin-2 and Mortality Outcomes in End-Stage Renal Disease with Heart Failure as a Comorbidity.以心力衰竭为合并症的终末期肾病中血管生成素-2与死亡率结局
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241305101. doi: 10.1177/10760296241305101.
2
Angiopoietins as Predictor Indexes in COVID-19 Patients in Delta and Omicron Waves.血管生成素作为德尔塔和奥密克戎毒株流行期新冠患者的预测指标
Curr Issues Mol Biol. 2024 Apr 26;46(5):3975-3989. doi: 10.3390/cimb46050245.
3
Endotheliopathy in Acute COVID-19 and Long COVID.急性 COVID-19 和长新冠中的血管内皮病。
Int J Mol Sci. 2023 May 4;24(9):8237. doi: 10.3390/ijms24098237.
4
IFN-γ transforms the transcriptomic landscape and triggers myeloid cell hyperresponsiveness to cause lethal lung injury.IFN-γ 改变转录组图谱，并引发髓样细胞超反应性，导致致命性肺损伤。
Front Immunol. 2022 Sep 20;13:1011132. doi: 10.3389/fimmu.2022.1011132. eCollection 2022.
5
Outcomes of lung cancer surgery in patients with COVID-19 history: a single center cohort study.有 COVID-19 病史的肺癌手术患者的结局：一项单中心队列研究。
Gen Thorac Cardiovasc Surg. 2023 Mar;71(3):175-181. doi: 10.1007/s11748-022-01871-x. Epub 2022 Sep 14.
6
Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor.通过生物信息学和系统生物学分析识别新冠病毒病药物治疗中与炎症药物及药物相互作用相关的药物性肝损伤：孕烷X受体的作用
Front Pharmacol. 2022 Aug 1;13:804189. doi: 10.3389/fphar.2022.804189. eCollection 2022.
7
Soluble RAGE as a Prognostic Marker of Worsening in Patients Admitted to the ICU for COVID-19 Pneumonia: A Prospective Cohort Study.可溶性晚期糖基化终末产物受体作为新型冠状病毒肺炎入住重症监护病房患者病情恶化的预后标志物：一项前瞻性队列研究
J Clin Med. 2022 Aug 5;11(15):4571. doi: 10.3390/jcm11154571.
8
Vasculopathy in COVID-19.COVID-19 相关血管病变。
Blood. 2022 Jul 21;140(3):222-235. doi: 10.1182/blood.2021012250.
9
Risk stratification of individuals undergoing surgery after COVID-19 recovery.新冠病毒感染康复后接受手术患者的风险分层
Br J Anaesth. 2022 Jan;128(1):e37-e39. doi: 10.1016/j.bja.2021.09.026. Epub 2021 Oct 9.
10
Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients: outcome and time-course of clinical and biological parameters.COVID-19患者呼吸衰竭的体外膜肺氧合：临床和生物学参数的结果及时间进程
Can J Anaesth. 2020 Oct;67(10):1486-1488. doi: 10.1007/s12630-020-01727-z. Epub 2020 Jun 1.
本文引用的文献
1
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.越来越多的证据表明，在新冠病毒病治疗中，抗TNF治疗需要优先进行试验。
Lancet Rheumatol. 2020 Nov;2(11):e653-e655. doi: 10.1016/S2665-9913(20)30309-X. Epub 2020 Sep 5.
2
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
3
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.严重和危重新冠肺炎中的细胞因子升高：快速系统评价、荟萃分析，并与其他炎症综合征比较。
Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.
4
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联：一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
5
Is a "Cytokine Storm" Relevant to COVID-19?“细胞因子风暴”与新冠病毒病有关吗？
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154. doi: 10.1001/jamainternmed.2020.3313.
6
Severe Covid-19 disease: rather AVDS than ARDS?重症新冠病毒疾病：是急性血管内弥漫性凝血而非急性呼吸窘迫综合征？
Crit Care. 2020 Jun 11;24(1):327. doi: 10.1186/s13054-020-02972-w.
7
Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.血管生成素-2 作为内皮细胞激活的标志物，是预测 COVID-19 患者入住重症监护病房的良好预测因子。
Angiogenesis. 2020 Nov;23(4):611-620. doi: 10.1007/s10456-020-09730-0. Epub 2020 May 27.
8
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
9
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
10
Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients.循环中血管生成素-2水平过高是危重症内科患者死亡的有力预测指标。
Crit Care. 2008;12(6):R147. doi: 10.1186/cc7130. Epub 2008 Nov 21.
Zotero 插件